Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Verisante Technology Inc V.VER.H

Alternate Symbol(s):  VRSEF

Verisante Technology, Inc. is a Canada-based company. The Company does not operate any active business other than to identify and complete a reverse takeover (RTO) with a company in one of its target sectors that demonstrates significant growth potential and/or value creation opportunities for shareholders. The Company may pursue a target in any industry, it intends to focus its search on companies that meet its acquisition target characteristics within the life sciences sectors.


TSXV:VER.H - Post by User

Bullboard Posts
Post by andyranon Sep 19, 2012 10:11am
176 Views
Post# 20384904

Verisante Technology, Inc. Announces Exclusive Dis

Verisante Technology, Inc. Announces Exclusive Dis

Very good news. Just another of the many pieces falling into place.

https://verisante.com/news/86/verisante-technology-inc-announces-exclusive-distribution-agreement-with-bo-pharma-bv-for-benelux-region/

“BO-Pharma is the largest independent distributor of medical devices in the Benelux region,” said Thomas Braun, President & CEO of Verisante. “With the Benelux market outselling the UK and Germany in some dermatological and skin care devices, our partnership with BO-Pharma provides us a strong foothold in this important region. BO-Pharma will not only distribute Aura™, but can also support technical training and servicing in the region.”

“Impressive clinical study results show that Aura™, through speed and accuracy, is a device that can revolutionize the way skin cancer is diagnosed,” said Dr. Henk-Peter Oonk, CEO of BO-Pharma. “The Netherlands has historically been very quick to adopt new, disruptive medical technologies, and we are confident this trend will continue with Aura™.”

Bullboard Posts